KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CRISPR Therapeutics AG (CRSP) Current Taxes (2016 - 2025)

CRISPR Therapeutics AG (CRSP) has disclosed Current Taxes for 11 consecutive years, with $1.1 million as the latest value for Q4 2025.

  • Quarterly Current Taxes rose 146.78% to $1.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.1 million through Dec 2025, up 146.78% year-over-year, with the annual reading at $1.1 million for FY2025, 146.78% up from the prior year.
  • Current Taxes hit $1.1 million in Q4 2025 for CRISPR Therapeutics AG, down from $3.4 million in the prior quarter.
  • In the past five years, Current Taxes ranged from a high of $4.5 million in Q2 2021 to a low of $135000.0 in Q4 2022.
  • Historically, Current Taxes has averaged $1.7 million across 5 years, with a median of $975500.0 in 2024.
  • Biggest five-year swings in Current Taxes: skyrocketed 1081.69% in 2021 and later crashed 95.88% in 2023.
  • Year by year, Current Taxes stood at $724000.0 in 2021, then plummeted by 81.35% to $135000.0 in 2022, then soared by 224.44% to $438000.0 in 2023, then rose by 2.97% to $451000.0 in 2024, then skyrocketed by 146.78% to $1.1 million in 2025.
  • Business Quant data shows Current Taxes for CRSP at $1.1 million in Q4 2025, $3.4 million in Q3 2025, and $715000.0 in Q2 2025.